Veru Valuation
Is VERU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VERU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VERU ($0.68) is trading below our estimate of fair value ($13.9)
Significantly Below Fair Value: VERU is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VERU?
Key metric: As VERU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is VERU's PS Ratio? | |
|---|---|
| PS Ratio | 7x |
| Sales | US$14.09m |
| Market Cap | US$91.91m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.4x |
| Enterprise Value/EBITDA | -1.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does VERU's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 72.5x | ||
SHOT Safety Shot | 278.3x | n/a | US$52.8m |
PAVS Paranovus Entertainment Technology | 9.9x | n/a | US$62.6m |
NHTC Natural Health Trends | 1.5x | n/a | US$64.3m |
MED Medifast | 0.3x | -13.4% | US$194.9m |
VERU Veru | 7x | 40.8% | US$91.9m |
Price-To-Sales vs Peers: VERU is good value based on its Price-To-Sales Ratio (7x) compared to the peer average (72.5x).
Price to Sales Ratio vs Industry
How does VERU's PS Ratio compare vs other companies in the US Personal Products Industry?
Price-To-Sales vs Industry: VERU is expensive based on its Price-To-Sales Ratio (7x) compared to the US Personal Products industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is VERU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 7x |
| Fair PS Ratio | 6.1x |
Price-To-Sales vs Fair Ratio: VERU is expensive based on its Price-To-Sales Ratio (7x) compared to the estimated Fair Price-To-Sales Ratio (6.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$0.68 | US$3.40 +403.7% | 44.0% | US$5.00 | US$1.00 | n/a | 5 |
| Nov ’25 | US$0.76 | US$3.40 +345.3% | 44.0% | US$5.00 | US$1.00 | n/a | 5 |
| Oct ’25 | US$0.77 | US$3.40 +343.8% | 44.0% | US$5.00 | US$1.00 | n/a | 5 |
| Sep ’25 | US$0.82 | US$3.40 +315.4% | 44.0% | US$5.00 | US$1.00 | n/a | 5 |
| Aug ’25 | US$0.89 | US$3.40 +282.4% | 44.0% | US$5.00 | US$1.00 | n/a | 5 |
| Jul ’25 | US$0.88 | US$3.44 +291.5% | 41.7% | US$5.00 | US$1.20 | n/a | 5 |
| Jun ’25 | US$1.01 | US$3.44 +240.6% | 41.7% | US$5.00 | US$1.20 | n/a | 5 |
| May ’25 | US$1.49 | US$3.33 +123.7% | 37.4% | US$5.00 | US$2.00 | n/a | 3 |
| Apr ’25 | US$0.76 | US$4.00 +426.3% | 54.0% | US$7.00 | US$2.00 | n/a | 3 |
| Mar ’25 | US$0.64 | US$4.50 +603.1% | 55.6% | US$7.00 | US$2.00 | n/a | 2 |
| Feb ’25 | US$0.49 | US$4.50 +818.4% | 55.6% | US$7.00 | US$2.00 | n/a | 2 |
| Jan ’25 | US$0.72 | US$4.50 +525.0% | 55.6% | US$7.00 | US$2.00 | n/a | 2 |
| Dec ’24 | US$1.01 | US$3.33 +230.0% | 78.7% | US$7.00 | US$1.00 | n/a | 3 |
| Nov ’24 | US$0.87 | US$3.33 +283.3% | 78.7% | US$7.00 | US$1.00 | US$0.76 | 3 |
| Oct ’24 | US$0.72 | US$3.33 +363.6% | 78.7% | US$7.00 | US$1.00 | US$0.77 | 3 |
| Sep ’24 | US$1.04 | US$3.33 +220.5% | 78.7% | US$7.00 | US$1.00 | US$0.82 | 3 |
| Aug ’24 | US$1.20 | US$4.00 +233.3% | 89.0% | US$9.00 | US$1.00 | US$0.89 | 3 |
| Jul ’24 | US$1.19 | US$4.25 +257.1% | 73.2% | US$9.00 | US$1.00 | US$0.88 | 4 |
| Jun ’24 | US$0.98 | US$4.25 +335.5% | 73.2% | US$9.00 | US$1.00 | US$1.01 | 4 |
| May ’24 | US$1.34 | US$8.00 +497.0% | 59.3% | US$15.00 | US$2.00 | US$1.49 | 4 |
| Apr ’24 | US$1.16 | US$10.00 +762.1% | 51.5% | US$15.00 | US$2.00 | US$0.76 | 4 |
| Mar ’24 | US$3.76 | US$11.25 +199.2% | 47.6% | US$15.00 | US$2.00 | US$0.64 | 4 |
| Feb ’24 | US$5.90 | US$18.80 +218.6% | 48.2% | US$31.00 | US$3.00 | US$0.49 | 5 |
| Jan ’24 | US$5.28 | US$18.80 +256.1% | 48.2% | US$31.00 | US$3.00 | US$0.72 | 5 |
| Dec ’23 | US$5.48 | US$25.60 +367.2% | 35.9% | US$36.00 | US$10.00 | US$1.01 | 5 |
| Nov ’23 | US$12.41 | US$35.20 +183.6% | 30.1% | US$55.00 | US$24.00 | US$0.87 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Oddity Tech
US$2.5b
Operates as a consumer tech company that builds digital-first brands for the beauty and wellness industries in the United States and internationally.
ODD
US$45.56
7D
14.6%
1Y
32.5%
Reynolds Consumer Products
US$5.8b
Produces and sells products in cooking, waste and storage, and tableware product categories in the United States and internationally.
REYN
US$27.76
7D
1.9%
1Y
6.4%
USANA Health Sciences
US$750.2m
Develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe.
USNA
US$39.90
7D
-1.1%
1Y
-15.4%